Several other research firms also recently commented on OMCL. BidaskClub downgraded Amyris from a hold rating to a sell rating in a report on Thursday, June 27th. Craig Hallum upgraded PROS from a hold rating to a buy rating and raised their price objective for the stock from $36.00 to $60.00 in a report on Friday, April 26th. TheStreet downgraded Trinity Industries from a b rating to a c rating in a report on Thursday, April 25th. Zacks Investment Research upgraded Triple-S Management from a hold rating to a buy rating and set a $26.00 price objective on the stock in a report on Monday, April 29th. Finally, Benchmark restated a hold rating on shares of Western Digital in a report on Friday, April 26th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Omnicell presently has a consensus rating of Buy and an average price target of $79.89.
Shares of OMCL stock opened at $74.23 on Friday. Omnicell has a 52-week low of $52.20 and a 52-week high of $92.59. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.96 and a quick ratio of 1.47. The company has a market cap of $2.83 billion, a price-to-earnings ratio of 48.52, a P/E/G ratio of 2.22 and a beta of 1.13. The business’s 50 day simple moving average is $82.79.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, April 25th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.38. The firm had revenue of $202.50 million during the quarter, compared to analyst estimates of $199.72 million. Omnicell had a return on equity of 11.10% and a net margin of 4.74%. Omnicell’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period last year, the company earned $0.29 EPS. On average, equities research analysts anticipate that Omnicell will post 2.06 earnings per share for the current fiscal year.
In other news, EVP Scott Peter Seidelmann sold 8,500 shares of Omnicell stock in a transaction on Friday, May 10th. The stock was sold at an average price of $81.68, for a total value of $694,280.00. Following the transaction, the executive vice president now directly owns 28,929 shares in the company, valued at approximately $2,362,920.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Randall A. Lipps sold 65,161 shares of Omnicell stock in a transaction on Monday, April 29th. The shares were sold at an average price of $63.77, for a total value of $4,155,316.97. The disclosure for this sale can be found here. Insiders sold a total of 137,818 shares of company stock worth $10,075,315 over the last quarter. Company insiders own 2.77% of the company’s stock.
Several large investors have recently made changes to their positions in the company. LS Investment Advisors LLC increased its holdings in shares of Omnicell by 5.6% in the 1st quarter. LS Investment Advisors LLC now owns 2,460 shares of the company’s stock valued at $199,000 after acquiring an additional 130 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Omnicell by 7.9% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,917 shares of the company’s stock valued at $236,000 after acquiring an additional 213 shares during the period. Oregon Public Employees Retirement Fund increased its holdings in shares of Omnicell by 1.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 15,347 shares of the company’s stock valued at $1,241,000 after acquiring an additional 277 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Omnicell by 125.0% in the 1st quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock valued at $44,000 after acquiring an additional 300 shares during the period. Finally, Parallel Advisors LLC purchased a new position in shares of Omnicell in the 1st quarter valued at $28,000. Institutional investors and hedge funds own 97.02% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Further Reading: Trading Stocks – What are percentage gainers?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.